And we thought this was over and done.

mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines

Company to begin Phase 3 trial of mRNA-1083 in adults 50 years and above (October 4, 2023. Press Release from Moderna).

Of course, Moderna isn’t showing anyone that reactogenicity and safety profile data for this new combo mRNA COVID-19 and Influenza jab that they are working handin glove with the FDA to rush through the clinical trials… All we can do is hope that some investor decides to leak an internal slide deck summarizing the data as happened previously.

Posted in

Iron Will

Leave a Comment

You must be logged in to post a comment.